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ABSTRACT
Background In the curative-intent treatment of locally
advanced lung cancer, significant morbidity and mortality
can result from thoracic radiation therapy. Symptomatic
radiation pneumonitis occurs in one in three patients and
can lead to radiation-induced fibrosis. Local failure occurs
in one in three patients due to the lungs being a dose-
limiting organ, conventionally restricting tumour doses
to around 60 Gy. Functional lung imaging using positron
emission tomography (PET)/CT provides a geographic map
of regional lung function and preclinical studies suggest
this enables personalised lung radiotherapy. This map of
lung function can be integrated into Volumetric Modulated
Arc Therapy (VMAT) radiotherapy planning systems,
enabling conformal avoidance of highly functioning regions
of lung, thereby facilitating increased doses to tumour
while reducing normal tissue doses.
Methods and analysis This prospective interventional
study will investigate the use of ventilation and perfusion
PET/CT to identify highly functioning lung volumes and
avoidance of these using VMAT planning. This single-arm
trial will be conducted across two large public teaching
hospitals in Australia. Twenty patients with stage III
non-small cell lung cancer will be recruited. All patients
enrolled will receive dose-escalated (69 Gy) functional
avoidance radiation therapy. The primary endpoint is
feasibility with this achieved if ≥15 out of 20 patients meet
pre-defined feasibility criteria. Patients will be followed for
12 months post-treatment with serial imaging, biomarkers,
toxicity assessment and quality of life assessment.
Discussion Using advanced techniques such as VMAT
functionally adapted radiation therapy may enable safe
moderate dose escalation with an aim of improving local
control and concurrently decreasing treatment related
toxicity. If this technique is proven feasible, it will inform
the design of a prospective randomised trial to assess
the clinical benefits of functional lung avoidance radiation
therapy.

Strengths and limitations of this study
►► This is a novel trial interventional trial integrat-

ing
Galligas/68Ga-macroaggregated
albumin
respiratory-gated (4-dimensional) ventilation/perfusion (positron emission tomography/CT) functional
lung imaging into radiation treatment planning.
►► Volumetric modulated arc therapy (VMAT) planning
used in this trial aims to allow for moderate dose
escalation to the primary only, while respecting conventional normal tissue toxicity constraints.
►► This single-arm study will assess the technical feasibility of delivering personalised VMAT radiation.
►► Radiation plans will be personalised to an individual’s tumour location and spatial lung function.
►► This single arm feasibility study is unable to assess
effectiveness of reduction in pulmonary toxicity or
enhanced tumour control but will nonetheless provide valuable information about the feasibility of
conducting a larger-scale randomised trial.

Ethics and dissemination This study was approved by
the Peter MacCallum Human Research Ethics Committee.
All participants will provide written informed consent.
Results will be disseminated via publications.
Trials registration number NCT03569072; Pre-results

INTRODUCTION
In the curative treatment of locally advanced
non-small cell lung cancer (NSCLC), significant treatment-related morbidity and even
mortality can result from thoracic radiation therapy. The predominant mechanism behind treatment-
related toxicity is
radiation effects on the lung manifesting as
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Integration of functional lung imaging into treatment planning
Lung imaging using inhaled Galligas and intravenously
administered 68Ga- macroaggregated albumin (MAA)
enables acquisition of four-dimensional (4D) ventilation
and perfusion (V/Q) positron emission tomography
(V/Q, positron emission tomography (PET)/CT).6 7
This provides a 3D map of lung V/Q.8 Previous work has
demonstrated a relationship between radiation therapy
dose and change in V/Q as visualised V/Q PET/CT.9 10
We have shown strong correlations between V/Q PET/
CT functional volumes and pulmonary function test
parameters.11
Planning studies conducted on participants in the
observational GalliPET clinical trial have shown feasibility
of radiation therapy treatment planning personalised to
an individual’s lung functional distribution; it has been
demonstrated that integrating V/Q PET/CT information
in radiation therapy planning can significantly reduce
dose to functional lung.12 13 Systematic review of the literature has demonstrated reductions in functional lung
dose can be achieved with the mean functional volume
receiving 20 Gy reduced by: 4.42% (95% CI 1.66% to
7.18%) for perfusion, 4.41% (95% CI 2.37% to 6.45%) for
ventilation and 4.19% (95% CI 2.34% to 6.04%) overall
when plans were optimised based on functional lung
imaging.14 The mean functional lung dose was reduced
by: 1.98 Gy (0.57: 3.39) for perfusion, 2.63 Gy (0.14: 5.12)
for ventilation and 2.18 Gy (1.09: 3.26) overall when plans
were optimised using functional lung imaging.14
Advances in radiation therapy planning
This functional map of lung can be integrated into volumetric modulated arc therapy (VMAT) advanced radiation
therapy planning which can optimise radiation planning
to avoid functional regions of lung. A number of studies
have demonstrated improved dosimetry compared with
other radiation therapy techniques for NSCLC.15 VMAT
may enable safe dose escalation above the standard dose
of 60 Gy with accurate normal tissue definition, motion
management and functional avoidance. Another advance
to VMAT planning is the introduction of more advanced
techniques such as the use of non-coplanar arcs. This
has been shown to significantly decrease heart dose by
20%–30% in patients with lower lobe tumours treated
with 74 Gy in 37 fractions.16
2

Radiobiological basis for dose escalation
74 Gy in 37 fractions at 2 Gy per fraction has been established as the maximum tolerated safe dose in multiple
phase 1/2 dose escalation studies.17 This was used as the
basis for the phase 3 trial, RTOG 0617.2 This demonstrated inferior local control and worse survival in the
dose escalation arm.2 18 Further analysis of the RTOG
0617 trial suggests that worse outcomes may relate to
increased dose to organs at risk, especially the heart
which may be able to be reduced with advanced planning techniques and a smaller volume being irradiated at a higher dose using a simultaneous-integrated
boost technique.5 18 With the current standard of care
dose of 60 Gy mediastinal nodal failure is rare.19 Therefore, there is renewed interest in escalating dose to the
primary tumour which is a common site of failure while
treating the nodal volumes to a standard dose of 60 Gy.20
As mediastinal nodes are centrally located, maintaining
a standard dose to these regions has the added benefit
of not increasing dose to the central organs at risk
such as the heart, oesophagus and proximal bronchial
tree. Further analysis of dose escalation trials suggest
there may be an overall survival benefit to a dose escalated approach if it can be delivered without treatment
prolongation.21 This form of dose escalation has not
been tested with a consistent manner using advanced
radiation therapy planning techniques.
METHODS AND ANALYSIS
This is a prospective single-arm interventional clinical trial
assessing the technical feasibility of functionally adapted
lung radiation therapy using V/Q PET/CT imaging and
VMAT planning. The primary intervention is VMAT radiation therapy optimised to avoid regions of functional
lung delivered to a total dose of 60 Gy in 30 fractions to
the primary and nodal planning target volume. A simultaneous integrated boost will be delivered to the primary
tumour to a total dose of 69 Gy in 30 fractions. The trial
schema is demonstrated in figure 1. The trial plans to
recruit a total of 20 patients over two tertiary teaching
hospitals in Melbourne, Australia.
Inclusion criteria
Age ≥18 years.
Informed consent documented and consent form
signed.
►► Histologically or cytologically confirmed NSCLC.
►► ECOG performance status 0–2 within 2 weeks prior to
registration.
►► Locally advanced disease (stage IIIA, IIIB, IIIC AJCC,
eighth ed.) as confirmed on staging 18F-fluorodeoxyglucose (FDG)-PET/CT with no evidence of metastatic
intracranial disease on CT brain with contrast or MRI.
►► Planned for treatment with curative intent.
►►
►►

Exclusion criteria
Participant is not able to tolerate supine position for
imaging.

►►
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symptomatic radiation pneumonitis which occurs in up to
one in three patients with fatal pneumonitis occurring in
2% of patients.1 The risk of pneumonitis is related to the
dose and volume of lung irradiated. Current lung dose
volume constraints simplistically assume that the lungs are
anatomically and functionally homogeneous. A number
of factors increase pneumonitis risk further including the
use of concurrent chemotherapy, interstitial lung disease
and age.1 The need to limit lung dose and other organs
for safety reasons may contribute to the high local failure
rate in stage III disease in one in three patients.2–5

Open access

►►
►►

If history of a prior extrathoracic invasive malignancy
(except non-melanomatous skin cancer) must be free
from recurrence for a minimum of 3 years at the time
of registration.
Prior radiation therapy to the lungs or mediastinum.
Prior known history of interstitial lung disease.

Trial objectives
The primary objective of this study is to assess the technical feasibility of the delivery of personalised functional
lung radiation therapy using V/Q PET/CT. This study
will be considered feasible if all criteria defined below are
achieved for ≥15 out of 20 patients.
Feasibility will be considered to have been achieved
for a given patient if all of the following criteria are me
when functional plans are compared with conventional
anatomical plans: (A) Reduction in mean functional lung
dose of ≥2 Gy and functional lung volume receiving 20 Gy
of ≥4%; (B) Mean heart dose is ≤30 Gy and relative heart
volume receiving 50 Gy is <25%.
The secondary objectives are:
1. To determine the incidence of grade ≥2 clinical or
radiological pneumonitis after high dose functionally
adapted radiation therapy.
2. To determine the incidence of grade ≥2 acute and late
toxicities.
3. To quantify regional ventilation loss and regional perfusion loss on post treatment V/Q PET/CT following
functionally adapted lung radiation therapy and its relationship to spirometry and exercise tolerance.
4. To assess the relationships of cytokine release in patient’s plasma with grade ≥2 radiation pneumonitis.
5. To assess the associations between:
a. Ventilation PET/CT with inhale/exhale CT ventilation.
b. Perfusion PET/CT with dual energy CT iodine
mapping (a surrogate for pulmonary perfusion).

6. To assess patient reported quality of life outcomes using the FACT-L quality of life questionnaire.
7. To assess incidence of complete metabolic response
3-month post-treatment FDG-PET/CT.
8. To assess progression-free survival at 12 months following completion of trial radiation therapy (defined by
RECIST V.1.1).
9. To assess overall survival at 12 months following completion of trial radiation therapy.
The exploratory objectives are:
1. To assess the feasibility of conducting a radiation induced lymphocyte apoptosis assay.
2. To investigate the utility of mid-treatment cardiac biomarker testing and pretreatment coronary calcium
scoring to predict patients at greater risk of radiation
induced cardiac toxicity.
3. To correlate primary and nodal disease metabolic parameters seen on pretreatment and post-
treatment
FDG-PET/CT with dual energy CT iodine quantification.
4. To assess circulating tumour-DNA levels as a predictor
of treatment response.
V/Q PET/CT procedure
The radiopharmaceuticals used in this study will be
synthesised onsite by a qualified radio pharmacist using
methods we have previously validated by our group.7 10
68
Ga will be eluted from our 68Ge/68Ga generator and
used to label the appropriate precursor. 68Ga-Galligas
is prepared using a Technegas generator except that
the radionuclide technetium-
99m is replaced with
gallium-68 in the carbon crucible inserted into the Technegas synthesis unit. 68Ga-MAA is prepared as follows: A
commercially available kit of MAA is washed three times
with sterile milli-Q water dispensed into 1 mL aliquots
with each aliquot containing MAA particles of between
250 and 700 thousand particles. Gallium-68 obtained

Figure 1 Demonstrates the trial schema from screening to the final assessment at 12 months post-treatment. AEs, adverse
events; FDG, fluorodeoxyglucose; PET, positron emission tomography; RT, radiation therapy; VMAT, Volumetric Modulated Arc
Therapy; V/Q, ventilation and perfusion.
Bucknell N, et al. BMJ Open 2020;10:e042465. doi:10.1136/bmjopen-2020-042465
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Personalised functional adapted VMAT radiation therapy
Technical description
Treatment planning will be done using the Varian Medical
Systems, Palo Alto, California, Eclipse V.15.5 computerised radiation therapy planning system. At least two
VMAT arcs will be used to deliver the radiation therapy.
The 360° arcs are to be avoided to minimise dose to the
contralateral lung. It is expected individual arc length will
typically be between 180° and 240°.

Functional lung volumes
Nuclear medicine physicians in conjunction with the
radiation oncologists will define visually adapted functional lung subvolumes. The definitions and description
of each functional lung grouping are described below.
A 30% threshold was determined to separate regions of
lung with higher potential function. On meta-analysis,
this threshold was the most common threshold used
volumes and
when determining functional lung sub-
similar to previously published thresholds using VQ
PET.14 24
Name (full)

Short
name

Perfused

Q Lung

Any Lung parenchyma containing 68Ga-MAA
contoured using a visually adapted threshold
that is confirmed by a physician.

Well
Perfused

WQ
Lung

Contour defined as 68Ga-MAA uptake greater
than 30% of max.

Ventilated

Vent
Lung

Any Lung parenchyma containing Galligas
contoured using a visually adapted threshold
that is confirmed by a physician. If there was
significant clumping of the Galligas in the central
airways was observed this was excluding activity
four SD above the mean25

Well
Ventilated

WVent
Lung

Contour defined as Galligas uptake greater than
30% of max.

Description

Galligas, 68Ga-carbon ultrafine aerosols; MAA, macroaggregates of human
albumin.

These volumes are imported as DICOM structures into
Eclipse. After visual verification, the radiation oncologist
then uses these to generate the following opimisation structures. A graphical description of the components of all
functional lung volumes is provided in figure 2.
Optimisation
prioritisation

Name (full)

Name

Description

1

High
functioning

Lung HF

Intersection of WVent lung and
WQ lung, excluding PTV

2

Functioning

Lung F

Intersection of vent and Q
contours excluding lung HF
excluding PTV

3

Perfused

Lung P

Any lung parenchyma containing
68
Ga-macroaggregated albumin
contoured using a visually
adapted threshold that is
confirmed by a physician.
Excluding lung HF, lung F,
excluding PTV

4

Ventilated

Lung V

Any lung parenchyma containing
Galligas contoured using a
visually adapted threshold that
is confirmed by a physician.
Excluding lung HF, lung F, lung P,
excluding PTV

Radiation therapy volumes
Target volumes will be defined as per standard practice
including the primary tumour and nodal gross tumour
volumes (GTV), internal target volumes (ITV) and planning target volumes (PTV). GTV incorporating respiratory motion on 4D CT, the internal gross tumour volume
(IGTV) will be contoured for the primary tumour. ITV
as defined by ICRU70 will be used to take into account
tumour movement through respiration and a margin
for subclinical spread.22 Target delineation and margins
applied to primary tumour and nodal volumes are as per
institutional protocol including mandatory use of 4D CT,
FDG-PET/CT fusion and diagnostic contrast enhanced
CT.
Boost volume definition: The proximal bronchial tree will
have an isotropic 3 mm PRV expansion named proximal
bronchial tree PRV. The boost volume (IGTV_6900) will be
given to the IGTV of the primary tumour alone minus the
proximal bronchial tree PRV. Normal tissue contouring will
follow the RTOG 1106 contouring atlas.23

The expected outcome of these optimisation objectives is demonstrated in figure 3 where axial and coronal
slices demonstrate the 20 Gy isodose line. In the functionally adapted plan there is less of the 20 Gy isodose line
overlapping with high functioning and functioning lung
segments.

4
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from the generator is buffered with acetate buffer to pH
6–7 before adding to the MAA aliquot. The suspension
mixture is allowed to incubate for 1 min at 90°C after the
addition of radioactivity for the radiolabeling process.
Quality control tests was performed in accordance with
the British Pharmacopoeia for radiolabelled MAA before
the compound is released for clinical use.
The methodology of the V/Q PET/CT will be as follows:
1. A peripheral intravenous catheter is installed in the
arm.
2. Participant inhales approximately 5 MBq of 68Ga-
Galligas, in semi-supine position, using the same technique as for Technegas.
3. A chest 4D-CT acquisition is performed (140 kVp, 30–
40 mA, axial scan time is breathing period +1 s.
4. Lung ventilation 3D list-mode respiratory gated PET
acquisition is started (2–3 bed positions, 5 min per bed
position). This acquisition will be reconstructed as
both a respiratory gated and ungated scan.
5. Without moving, approximately 20–40 MBq 68Ga-MAA
is injected intravenously, as a bolus, via the catheter.
The syringe is then flushed with normal saline.
mode respiratory gated
6. The lung perfusion 3D list-
PET acquisition is started (2–3 bed positions, 5 min per
bed position, exactly the same bed positions as for the
ventilation study). This acquisition will be reconstructed as both a gated and ungated scan.

Open access

Treatment planning
The investigational treatment will be prescribed ensuring
that 98% of the 60 Gy PTV is covered by 98% of the
dose. The 69 Gy in 30 fractions (9 Gy) boost sub-volume
(IGTV_6900) will aim to achieve 95% of the IGTV receives
100% of the boost dose (D95=100%). The maximum dose
to PTV (PTV max) must be contained within the IGTV.
This boost dose will be reduced if organ at risk planning
constraints cannot be met. This will be at the discretion
of the treating clinician. Dose constraints to organs at risk
are described in table 1. If dose reduction is necessary, this
event should be recorded and the D95% reported. Non-
coplanar arcs may be considered if technically feasible
and if this improves normal tissue sparing. It is expected
that majority of patients will receive concurrent cytotoxic
chemotherapy; the treating medical oncologist will determine the agents. Acceptable chemotherapy regimens
include weekly carboplatin and paclitaxel and 3 weekly
cisplatin and etoposide in accordance with Australian

guidelines.26 27 Appropriate patients will also be offered
adjuvant immunotherapy.28 This is not mandated by this
study protocol.
Treatment delivery
All patients will have a pretreatment dosimetric quality
assurance according to departmental VMAT quality assurance guidelines. Daily Cone Beam CT (CBCT) will be
performed with online soft tissue matching will ensure
that the target is within the PTV.
Statistical considerations
The study sample size is pragmatic and based on the clinically relevant number of patients needed to determine
the technical feasibility of the functional lung sparing
VMAT radiation therapy technique. Table 2 demonstrates
the 95% CIs for different scenarios of feasibility rates.
The study follow-up duration was designed to be pragmatic for a feasibility study while having enough follow-up

Figure 3 The arrows demonstrate the 20 Gy isodose line in radiation therapy plans optimised with conventional (anatomically
based) lung constraints (left) and integrating functional information from V/Q PET/CT (right). PET, positron emission tomography;
V/Q, ventilation and perfusion.
Bucknell N, et al. BMJ Open 2020;10:e042465. doi:10.1136/bmjopen-2020-042465

5

BMJ Open: first published as 10.1136/bmjopen-2020-042465 on 10 December 2020. Downloaded from http://bmjopen.bmj.com/ on August 3, 2021 by guest. Protected by copyright.

Figure 2 Demonstrates a spatial description of each of the lung subvolumes created by integrating functional information from
the V/Q PET/CT is used to create optimisation functional lung subvolumes which are used in VMAT radiation therapy planning.
PET, positron emission tomography; VMAT, Volumetric Modulated Arc Therapy; V/Q, ventilation and perfusion.
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Structure

Per protocol

Source

Max dose 0.03cc
Max dose 0.03cc

≤50 Gy
<63 Gy

13

Mean

<34 Gy

13

V40

<30%

 

V50

<25%

33

Mean

<20 Gy

5

Max dose 0.03cc

<70 Gy

13

Brachial plexus

Max dose 0.03cc

<63 Gy

13

Proximal bronchial tree

Max dose 1.0cc

<64.5 Gy

3

Great vessels (normal)

Max dose 0.03cc

<80 Gy

34

Great vessels (tumour involved) Max dose 0.03cc

<70 Gy

34

Bony spinal canal
Oesophagus
Heart

Metric

13

Lung dose constraints
Structure

Metric

Per protocol

Definition

Source

Lungs (anatomic)
Left+right lung-IGTV

Mean

<20 Gy

Mean dose to the whole anatomic lung

13

V30

<30%

Volume of structure (%) receiving ≥30 Gy

13 35

V20
V5

<35%
<66%

Volume of structure (%) receiving ≥20 Gy
Volume of structure receiving ≥5 Gy

13 35

duration to detect clinically significant toxicity. In the
context of NSCLC radiation therapy, late cardiac and
lung toxicity typically presents within a 12-month time
period. Our recent systematic review showed that functional lung imaging dose–response relationships plateau
around 6–12 months post-treatment.14 29
Main analysis of the primary endpoint will be performed
after all patients have been registered and completed
their 3-month follow-up assessment. A final analysis will
be performed at the completion of the study, which will
be 12 months after the final patient completes treatment.
Monitoring programmes
Prior to commencement of radiation therapy, contours
undergo peer review and sign off by a qualified radiation
oncologist. All radiation therapy plans undergo review by
a senior radiation therapist and senior medical physicist.
Pretreatment dosimetric quality assurance is required
prior to delivery of the first fraction.

13 35

All trial personnel are required to be qualified for
their designated role with suitable training provided and
credentials certified by the principal investigator. On
treatment, weekly clinical reviews are performed a credentialed physician. At these assessments, offline CBCT
assessment is performed to ensure adequate coverage of
target volumes and review organs at risk. Post-treatment
assessments must also be performed by a credentialed
physician.
Independent trial monitoring
An independent data monitoring committee will be
appointed and will convene with the purpose of:
►► Assessing quality issues related to radiation therapy.
►► Assessing the conduct and progress of the trial—
accrual, non-eligibility, treatment toxicity and serious
adverse events.
SAEs will be forwarded to the data monitoring
committee. If three SAEs are recorded during the trial,

Table 2 This demonstrates shows the exact 95% CIs for different scenarios of feasibility rates
Exact 95% CIs for rate estimate
No of feasible cases

Feasibility rate, %

Lower limit, %

Upper limit, %

15
16

75
80

51
56

91
94

17

85

62

97

18

90

68

99

19
20

95
100

75
83

100
100
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Table 1 This table demonstrates the normal tissue constraints used in the radiation therapy planning process
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Data collection and record retention
All data will be stored in reidentifiable form on Research
Electronic Data Capture in a password-
protected
computer database.30 Any paper data will be stored in
a locked filing cabinet in a secure building. Data will
be stored for a minimum of 7 years after publication of
study results, in accordance with Institutional guidelines
and the Australian Code for the Responsible Conduct of
Research. Patient confidentiality will be maintained at all
times.
Ethics and dissemination
This study was approved by the Peter MacCallum Human
Research Ethics Committee (HREC/18/PMCC/23).
Prior studies have demonstrated safety of V/Q PET/CT.10
The stochastic and deterministic risks of radiation doses
used in trial investigations and treatment have been carefully assessed and detailed in the trial participant information and consent form. The study results will be published
in peer-reviewed journals.

DISCUSSION
Advanced techniques such as VMAT functionally adapted
radiation therapy may enable safe moderate dose escalation without treatment prolongation with an aim of
improving local control and concurrently decreasing
treatment related toxicity. The long-
term results from
the RTOG 0617 trial demonstrated worse survival in
the dose-
escalation arm. Long-
term follow-
up suggests
this mechanism is primarily through radiation injury
to the central structures of the heart and oesophagus.18
Advanced imaging and VMAT planning allow these structures to be precisely defined and using strict normal tissue
constraints moderate dose escalation to the primary
tumour alone may enable safe dose escalation without
treatment prolongation.
The paradigm for the management of stage III lung
cancer has changed significantly with the introduction
of consolidation immunotherapy. Patients who receive
consolidation durvalumab in the PACIFIC trial demonyear overall survival to
strated an improvement in 3-
57.0% compared with 43.5% in the group randomised to
placebo.28 Although this treatment has improved survival
in this patient cohort, additional toxicities involved with
immunotherapy have been documented with pneumonitis occurring more frequently in patients treated
with immunotherapy.31 Prior radiation to the lungs is a
known risk factor for this toxicity.32 Advanced functional
imaging with V/Q PET/CT and planning to avoid highly
Bucknell N, et al. BMJ Open 2020;10:e042465. doi:10.1136/bmjopen-2020-042465

functional regions of lung may minimise this risk of
toxicity.
Currently, little is understood about why certain patients
experience radiation induced toxicity. The pretreatment,
mid-
treatment and post-
treatment imaging and blood
biomarkers being investigated in this trial in an exploratory manner may provide useful hypotheses to enable
further research into better understanding treatment
related toxicity. If feasible, this technique will allow a
prospective randomised trial to assess the clinical benefits
of functional lung avoidance radiation therapy.
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